"Phenylthiohydantoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thiohydantoin benzene derivative.
Descriptor ID |
D010669
|
MeSH Number(s) |
D03.383.129.308.432.555.868.650
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phenylthiohydantoin".
Below are MeSH descriptors whose meaning is more specific than "Phenylthiohydantoin".
This graph shows the total number of publications written about "Phenylthiohydantoin" by people in this website by year, and whether "Phenylthiohydantoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 3 | 4 |
2015 | 1 | 1 | 2 |
2016 | 0 | 3 | 3 |
2017 | 2 | 1 | 3 |
2018 | 1 | 2 | 3 |
2019 | 3 | 3 | 6 |
2020 | 2 | 0 | 2 |
2021 | 3 | 2 | 5 |
2022 | 1 | 2 | 3 |
2023 | 0 | 1 | 1 |
2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenylthiohydantoin" by people in Profiles.
-
Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor. Commun Biol. 2024 Apr 04; 7(1):411.
-
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1111-1120.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
-
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 2022 Nov; 18(35):3867-3874.
-
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med. 2022 04 19; 3(4):100613.
-
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 04 05; 39(1):110595.
-
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022 01; 601(7893):434-439.
-
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 12; 159:237-246.
-
Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate. 2021 09; 81(12):799-811.